Tezepelumab-Ekko
Brand name: Tezspire
Rank #377 of 500 drugs by total cost
$25.6M
Total Cost
5,900
Total Claims
$25.6M
Total Cost
289
Prescribers
$4,337
Cost per Claim
144
Beneficiaries
5,984
30-Day Fills
$89K
Avg Cost/Provider
20
Avg Claims/Provider
About Tezepelumab-Ekko
Tezepelumab-Ekko (sold as Tezspire) was prescribed 5,900 times by 289 Medicare Part D providers in 2023, costing the program $25.6M. At $4,337 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 374 | Perampanel (Fycompa) | $25.9M | 20,876 |
| 375 | Timolol Maleate (Timolol Maleate) | $25.8M | 1,129,537 |
| 376 | Amitriptyline Hcl (Amitriptyline Hcl) | $25.8M | 1,295,043 |
| 377 | Tezepelumab-Ekko (Tezspire) | $25.6M | 5,900 |
| 378 | Ponatinib Hcl (Iclusig) | $25.6M | 1,209 |
| 379 | Citalopram Hydrobromide (Citalopram Hbr) | $25.3M | 2,778,255 |
| 380 | Amoxicillin/Potassium Clav (Amoxicillin-Clavulanate Potass) | $25.3M | 2,207,997 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology